Trial Profile
Effect of TP-252 as adjunct therapy to endoscopic surveillance in young familial adenomatous polyposis patients and as adjunct therapy to 5-ASA for maintenance of remission in ulcerative colitis patients.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs Eicosapentaenoic acid free fatty acid (Primary)
- Indications Familial adenomatous polyposis; Ulcerative colitis
- Focus First in man; Therapeutic Use
- Sponsors Thetis Pharmaceuticals
- 23 May 2018 According to the Thetis Pharmaceuticals media release, this trial is expected to begin 2019.
- 22 Jan 2016 New trial record
- 19 Jan 2016 According to Thetis media release, company is planning to initiate this trial in 2017.